Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels

Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels

Background: The AEGIS-II (ApoA-I Event Reducing in Ischemic Syndromes-II; NCT03473223) trial evaluated CSL112, a human plasma-derived apolipoprotein A-I therapy, for reducing cardiovascular events after acute myocardial infarction (AMI). Given CSL112’s potential anti-inflammatory properties, we cond...

Full description

Saved in:
Bibliographic Details
Main Authors: Sem A.O.F. Rikken, MD, C. Michael Gibson, MD, MS, M. Cecilia Bahit, MD, Danielle Duffy, MD, Gerald Chi, MD, Serge Korjian, MD, Niekbachsh Mohammadnia, MD, Harvey White, DSc, Gaya Anschuetz, MS, Bronwyn A. Kingwell, PhD, Ton Oude Ophuis, MD, PhD, Jose C. Nicolau, MD, PhD, Renato D. Lopes, MD, PhD, Basil S. Lewis, MD, Saloua El Messaoudi, MD, PhD, Dragos Vinereanu, MD, PhD, Jurriën M. ten Berg, MD, PhD, Shaun G. Goodman, MD, MSc, Christoph Bode, MD, PhD, P. Gabriel Steg, MD, Peter Libby, MD, Kevin R. Bainey, MD, Arnoud W.J. van 't Hof, MD, PhD, Paul M. Ridker, MD, Kenneth W. Mahaffey, MD, Stephen J. Nicholls, MD, Roxana Mehran, MD, Robert A. Harrington, MD, Jan H. Cornel, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:JACC: Advances
Subjects:
apolipoprotein A-I
CSL112
inflammation
MACE
neutrophil-lymphocyte ratio
Online Access:http://www.sciencedirect.com/science/article/pii/S2772963X25001449
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items